uniQure (NASDAQ:QURE) Shares Gap Up – Time to Buy?

by · The Cerbat Gem

uniQure N.V. (NASDAQ:QURE – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $20.43, but opened at $21.80. uniQure shares last traded at $20.6120, with a volume of 1,384,480 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Monday, December 8th. Wells Fargo & Company cut their price target on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. Cantor Fitzgerald boosted their price objective on uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Stifel Nicolaus lowered their price objective on uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Finally, Leerink Partners dropped their target price on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a research report on Monday, November 10th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $60.82.

Get Our Latest Stock Report on uniQure

uniQure Stock Down 0.6%

The company has a market cap of $1.27 billion, a price-to-earnings ratio of -4.63 and a beta of 0.59. The stock has a 50-day simple moving average of $40.31 and a 200-day simple moving average of $26.47. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QURE – Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. As a group, analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Insider Activity at uniQure

In related news, Director Robert Gut sold 31,434 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84. Following the transaction, the director owned 40,145 shares in the company, valued at $1,094,352.70. This trade represents a 43.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack Kaye sold 38,810 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the sale, the director directly owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 314,560 shares of company stock valued at $12,362,568. Insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its stake in uniQure by 3.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 279,999 shares of the biotechnology company’s stock valued at $2,968,000 after buying an additional 10,019 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in uniQure in the first quarter worth about $3,218,000. Aberdeen Group plc lifted its holdings in uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company’s stock valued at $23,485,000 after acquiring an additional 706,216 shares during the last quarter. Rafferty Asset Management LLC bought a new position in shares of uniQure during the 1st quarter valued at about $875,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of uniQure during the 1st quarter valued at about $4,240,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Read More